Roche reports long-term capabilities of multiple sclerosis drug
The BTK inhibitor enabled near-complete suppression of disability progression for up to two years in individuals with relapsing multiple sclerosis (RMS), the new findings reveal.
List view / Grid view
News
New technology could enhance CAR T therapy manufacture
The innovative device could improve CAR T cell cancer immunotherapy and facilitate its use as a first-line therapy, research suggests.
New Eli Lilly acquisition to progress potential next-generation pain treatment
The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.
CHMP meeting highlights – May 2025
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
Major trial indicates potential of novel hypertension drug
The demonstrated safety and efficacy of the aldosterone synthase inhibitor suggest its potential in helping patients with hypertension to reach their blood pressure goal, according to the data.
FDA approval marks shift in diabetic retinopathy treatment
The ocular injection, now granted its third FDA approval, offers a more convenient treatment option for patients with vision loss.
Sanofi to enhance neurology pipeline with new acquisition
The acquisition aligns with one of Sanofi’s four strategic disease areas and supports the company in utilising its immunology expertise to address areas of unmet need.
BioNTech pledges major UK investment
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
New real-world data guidance could accelerate drug approvals
The MHRA’s consultation, announced on International Clinical Trials Day, is intended to support creation of innovative UK trials.
UK Government commits to long-term R&D funding
The announcement supports the UK Government’s broader plans for reformation of longer-term funding for the research and development sector.
Novo Nordisk CEO to exit role
Current market conditions in the pharmaceutical industry have driven the change to its executive leadership team, according to Novo Nordisk.
Takeda investigational drug shows efficacy in narcolepsy
If approved, the oral medicine could provide a first-in-class treatment option for eligible individuals with the chronic 24-hour disease.
GSK to expand hepatology pipeline with potential best-in-class therapy
The unique mechanism of action of efimosfermin supports its potential as a new standard-of-care in liver disease.
Novel breast cancer treatment approach significantly enhances survival
With its detailed safety data for chemotherapy and olaparib to treat early-stage breast cancer, the trial findings could lead to improved patient outcomes.
World-first approval supports AstraZeneca’s sustainability goals
Approval of the novel tool marks progress for both respiratory disease patients in the UK and reducing the global environmental impact of inhaled medicines.
